Impact of treatment suspension on health-related quality of life in the EMBARK trial: a post hoc analysis.
1/5 보강
[BACKGROUND] Enzalutamide was approved for high-risk biochemically recurrent (hrBCR) prostate cancer based on the EMBARK trial (NCT02319837; 17 December 2014-31 January 2023).
APA
Freedland SJ, De Giorgi U, et al. (2025). Impact of treatment suspension on health-related quality of life in the EMBARK trial: a post hoc analysis.. EClinicalMedicine, 87, 103429. https://doi.org/10.1016/j.eclinm.2025.103429
MLA
Freedland SJ, et al.. "Impact of treatment suspension on health-related quality of life in the EMBARK trial: a post hoc analysis.." EClinicalMedicine, vol. 87, 2025, pp. 103429.
PMID
40838196 ↗
Abstract 한글 요약
[BACKGROUND] Enzalutamide was approved for high-risk biochemically recurrent (hrBCR) prostate cancer based on the EMBARK trial (NCT02319837; 17 December 2014-31 January 2023). In EMBARK, treatment was suspended at week 37 if prostate-specific antigen (PSA) was <0.2 ng/mL and reinstated if PSA rose to ≥2.0 ng/mL with radical prostatectomy or ≥5.0 ng/mL without. This post hoc analysis assessed the impact of treatment suspension on health-related quality of life (HRQoL) to address overtreatment concerns.
[METHODS] Longitudinal change in HRQoL from treatment suspension at week 37 to subsequent assessments until week 109 was analyzed with mixed models for repeated measures (MMRM) and descriptively among these patients. Separate models were used to assess four patient-reported outcome (PRO) instruments-Brief Pain Inventory - short form, Functional Assessment of Cancer Therapy - Prostate, QoL Questionnaire - Prostate 25, and European QoL 5-Dimensions 5-Levels health questionnaire-with predefined clinically meaningful thresholds. Intention-to-treat analysis was used.
[FINDINGS] Treatment was suspended in 90% (321/355), 86% (304/355), and 67% (240/358) of participants treated with enzalutamide + leuprolide, enzalutamide monotherapy, and leuprolide alone, respectively. MMRM showed no meaningful change in any treatment arm after treatment suspension across all assessed PRO measures, except hormonal treatment-related symptoms, for which clinically meaningful improvement was observed after treatment suspension at week 61 for enzalutamide monotherapy, week 73 for leuprolide alone, and week 85 for enzalutamide + leuprolide. The descriptive analysis showed similar findings.
[INTERPRETATION] Enzalutamide ± leuprolide in patients with hrBCR improves metastasis-free survival versus leuprolide alone with no clinically meaningful changes in the measured HRQoL domains during treatment or after treatment suspension, with gradual improvement in hormonal treatment-related symptoms after treatment suspension in this selective clinical trial population. Further real-world studies are warranted to better explore the benefits of treatment suspension.
[FUNDING] This study was funded by Pfizer Inc. and Astellas Pharma Inc.
[METHODS] Longitudinal change in HRQoL from treatment suspension at week 37 to subsequent assessments until week 109 was analyzed with mixed models for repeated measures (MMRM) and descriptively among these patients. Separate models were used to assess four patient-reported outcome (PRO) instruments-Brief Pain Inventory - short form, Functional Assessment of Cancer Therapy - Prostate, QoL Questionnaire - Prostate 25, and European QoL 5-Dimensions 5-Levels health questionnaire-with predefined clinically meaningful thresholds. Intention-to-treat analysis was used.
[FINDINGS] Treatment was suspended in 90% (321/355), 86% (304/355), and 67% (240/358) of participants treated with enzalutamide + leuprolide, enzalutamide monotherapy, and leuprolide alone, respectively. MMRM showed no meaningful change in any treatment arm after treatment suspension across all assessed PRO measures, except hormonal treatment-related symptoms, for which clinically meaningful improvement was observed after treatment suspension at week 61 for enzalutamide monotherapy, week 73 for leuprolide alone, and week 85 for enzalutamide + leuprolide. The descriptive analysis showed similar findings.
[INTERPRETATION] Enzalutamide ± leuprolide in patients with hrBCR improves metastasis-free survival versus leuprolide alone with no clinically meaningful changes in the measured HRQoL domains during treatment or after treatment suspension, with gradual improvement in hormonal treatment-related symptoms after treatment suspension in this selective clinical trial population. Further real-world studies are warranted to better explore the benefits of treatment suspension.
[FUNDING] This study was funded by Pfizer Inc. and Astellas Pharma Inc.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
같은 제1저자의 인용 많은 논문 (3)
- Survival benefit associated with first-line androgen receptor pathway inhibitors for de novo metastatic castration-sensitive prostate cancer.
- Real-world outcomes following biochemical recurrence after definitive therapy with a short prostate-specific antigen doubling time: potential role of early secondary treatment.
- Retrospective Analysis of Racial Differences in Treatment Patterns and Prostate-Specific Antigen Responses Among Patients with Prostate Cancer Treated with Relugolix in the Veterans Health Administration.
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- Use and reporting of patient-reported outcomes in randomized controlled trials in non-Hodgkin lymphoma: a scoping review.
- Assessing the assessment: a scoping review of the mode of patient-reported outcome assessment in solid cancer clinical trials.
- Field observation as a method to guide patient-reported outcome measurement integration in community cancer centers.
- Loss of UFL1 confers enzalutamide resistance of prostate tumors by regulating METTL16-mediated m6A modification of EEF1A1 mRNA.
- CDK12 Inactivation Attenuates Prostate Cancer Progression by Inhibiting BNIP3-Mediated Mitophagy.
- Evaluating the Feasibility of an Electronic Patient-Reported Outcomes Platform Integrating Electronic Health Records and a Mobile Messaging App in Breast Cancer Radiotherapy: Retrospective Cross-Sectional Study.